NCT04541485View on ClinicalTrials.gov

To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 4, 2020

Primary Completion Date

March 3, 2021

Study Completion Date

March 23, 2021

Conditions
COVID-19 Patients
Interventions
DRUG

DWRX2003

Intramuscularly injection at pre-defined injection sites

DRUG

Placebo

Intramuscularly injection at pre-defined injection sites

Trial Locations (1)

06170

Deawoong pharmaceutical, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY